Our multi-institutional collaboration identifying mechanisms of acquired resistance to KRAS G12C inhibitors in cancer is now out @NEJM. This thread highlights our key findings. @AndrewAguirre @DanaFarber
Mark Awad
206 posts
Mark Awad
@DrMarkAwad
Chief, Thoracic Oncology, Memorial Sloan Kettering Cancer Center @MSKCancerCenter | Lung Cancer Immunotherapy Research | Tweets my own
- I'm honored to join the phenomenal thoracic group @MSKCancerCenter as we continue working with the global oncology community to advance care for our patients worldwide with groundbreaking new discoveries and practice-changing therapies. #LCSM mskcc.org/news-releases/…
- Does high tumor mutational burden (#TMB) impact immunotherapy outcomes in #NSCLC? This has been a challenging biomarker to interpret and incorporate into clinical practice. We looked at >1500 patients w/NSCLC treated with PD-(L)1 inhibitors: ja.ma/3Qrvf5y in @JAMAOnc.
- Excited to present this multi-institutional effort on mechanisms of resistance to KRAS G12C inhibitors in cancer at #AACR21 today. Wonderful collaboration with Shengwu Liu and the lab of Andy Aguirre @andrewaguirremd @DanaFarber. abstractsonline.com/pp8/#!/9325/pr…
- A major advance for patients with early stage non-small cell lung cancer with the FDA approval of neoadjuvant chemotherapy + nivolumab based on CheckMate-816. Thank you to all the clinical trial participants!
- Excited to be heading to Santa Monica for #TTLC with our research group! Very thankful to work with such kind and talented individuals every day @DanaFarber
- New data on the @Novartis KRAS G12C inhibitor JDQ443 out in @CD_AACR @KRASKickers aacrjournals.org/cancerdiscover…
- How do patients with NSCLC & very high PD-L1 levels ≥90% do with 1st-line pembrolizumab? Multi-institutional collaboration led by outstanding Elizabeth Jimenez Aguilar & Biagio Ricciuti now online @Annals_Oncology @BiagioMD @Elizabethjimag @DanaFarber academic.oup.com/annonc/advance…
- Now out in @JCO_ASCO, led by the outstanding @BiagioRicciutMD and @GLambertiMD, is our group's effort to elucidate mechanisms of resistance to PD-1 #immunotherapy in #lungcancer
- So great for me and Pasi Jänne to meet with @bjork5 @DanaFarber this morning! A huge thanks to all the patient advocates for their tireless support of lung cancer awareness and research. #WhiteRibbonProject #lcsm
- In lung cancer, we know the importance of detecting and targeting MET exon 14 skipping mutations, MET amplification, and MET fusions. Here, we describe another important molecular target: activating MET tyrosine kinase domain (TKD) mutations. #LCSM
- So great dining with some of our thoracic oncology team tonight in Chicago! Thank you to our faculty, fellows, and researchers for all the hard work advancing care for our patients with lung cancer @DanaFarber #ASCO22
- Why do some lung cancers have high PD-L1 expression and others are PD-L1 negative? Very talented @lfspurr and @GLambertiMD describe clinical & genomic correlates of PD-L1 expression in NSCLC at #AACR2020 talk today and published in @Annals_Oncology #LCSM sciencedirect.com/science/articl…
- Adagrasib now has FDA breakthrough designation for KRAS G12C mutant NSCLC! @kRasKickers ir.mirati.com/press-releases…
